Interventional Oncology Market 2025–2033: Market Overview and Competitive Landscape

According to FutureWise analysis, the Interventional Oncology Market in 2025 is US$2.85 billion, and is expected to reach US$5.03 billion by 2033 at a CAGR of 7.36%. The Interventional Oncology Market is centered on minimally invasive, image-guided methods utilized for the diagnosis and treatment of cancer. This market is witnessing substantial growth driven by a rising demand for targeted cancer therapies and ongoing advancements in imaging technologies. Presently, North America holds the largest market share, while the Asia-Pacific region is starting to emerge as a significant competitor in this sector. The increasing global incidence of cancer and the heightened demand for less invasive treatment options are propelling the expansion of interventional oncology. This field is becoming essential for cancer treatment, offering targeted therapies that typically result in faster recovery times and fewer side effects compared to traditional methods. These enhancements are supported by progress in imaging-guided therapies. Interventional oncology represents a vibrant subspecialty within interventional radiology, focused on the diagnosis, treatment, and management of cancers through minimally invasive, image-guided techniques. This cutting-edge field combines advanced imaging technologies with accurate therapeutic methods, allowing healthcare providers to target tumors while minimizing damage to adjacent healthy tissues effectively. Consequently, interventional oncology has profoundly altered cancer care by offering less invasive options to conventional surgical techniques, resulting in shorter recovery times, reduced complications, and improved quality of life for patients. Technological Advancements: The evolution of minimally invasive, image-guided ablation technologies is advancing alongside the incorporation of sophisticated imaging and navigation systems. There is an increasing focus on targeted cancer therapies, which is broadening the potential market for interventional devices. Furthermore, the market is experiencing growth due to continuous technological innovations in minimally invasive procedures.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Interventional Oncology Market trends that shall affect the overall market growth.

Request a Free Sample @

https://www.futurewiseresearch.com/contact.aspx?rpt=2336&type=requestsample

By Product

• Embolization Devices
• Radioembolic Agents
• Non-Radioactive Embolic Agents
• Ablation Devices
• Radiofrequency Ablation Devices
• Microwave Ablation Devices
• Cryoablation Devices
• Other Ablation Devices
• Support Devices
• Microcatheters
• Guidewires

By Procedure

• Thermal Tumour Ablation
• Non-thermal Tumour Ablation
• Transcatheter Arterial Chemoembolization
• Transcatheter Arterial Radioembolization/Selective Internal Radiation Therapy
• Transcatheter Arterial Embolization/Bland Embolization

By Cancer Type

• Liver Cancer
• Lung Cancer
• Bone Cancer
• Kidney Cancer
• Other Cancers

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Competitive Landscape in Interventional Oncology Market:

• Medtronic
• Boston Scientific
• BTG Plc.
• Terumo
• Merit Medical
• Sirtex
• Ethicon
• Cook Medical
• Teleflex
• HealthTronics
• MedWaves Medical
• IceCure Medical
• Interface Biomaterial BV
• Mermaid Medicals
• ABK Biomedical
• Guerbet
• Endo Shape
• Instylla
• Shape Memory Medical
• Monteris Medical
• Trisalus Lifesciences

Recent developments by key players in the Interventional Oncology Market:

Sirtex

• In July 2025, the U.S. Food and Drug Administration (FDA) approved SIR-Spheres® Y-90 resin microspheres for the treatment of unresectable hepatocellular carcinoma (HCC). This approval makes it the only radioembolization therapy in the United States that is authorized for both metastatic colorectal cancer (mCRC) and HCC.

Boston Scientific

• Acquisition of Intera Oncology (Nov 2024): Integrated the Intera 3000 Hepatic Artery Infusion Pump and floxuridine, enhancing treatment options for liver metastases.
• Boston Scientific offers a variety of interventional oncology and embolization products, including Y-90 microspheres, coils, beads, and cryoablation systems. Their goal is to provide targeted treatments that improve the lives of patients facing cancer and other serious diseases.

Buy now the latest version of this report: https://www.futurewiseresearch.com/checkout.aspx?ReportId=2336&license=multi

**Objectives of this Study: **

1. To provide a comprehensive analysis of the Interventional Oncology Market By Product, By Procedure, By Cancer Type and By Region.
2. To offer detailed insights into factors such as drivers, restraints, trends, and opportunities, as well as segmental and regional influences on market growth.
3. To evaluate current market trends and forecast micro-markets, presenting overall market projections in the form of data sets and PowerPoint presentations.
4. To predict the market size in key regions, including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

                                                                                                                
Flexible Delivery Model:

• We have a flexible delivery model and you can suggest changes in the scope/table of contents as per your requirement
• The customization services offered are free of charge with the purchase of any license of the report.
• You can directly share your requirements/changes to the current table of contents to: [email protected]